C-Peptide Is Not Recommended for Detecting Insulin Resistance
Routine C-peptide or insulin measurements are not recommended for assessing insulin resistance in clinical practice 1. The most recent and authoritative 2023 Diabetes Care guidelines explicitly state that in most people with diabetes or at risk for diabetes or cardiovascular disease, routine testing for insulin or proinsulin (and by extension C-peptide for this purpose) is not recommended, as these assays are useful primarily for research purposes 1.
Why C-Peptide Should Not Be Used for Insulin Resistance Detection
Guideline-Based Reasoning
The 2023 guidelines specifically address the polycystic ovary syndrome (PCOS) context—a classic insulin resistance condition—and conclude that it is unclear whether assessing insulin resistance through insulin or C-peptide measurement has any advantage over assessment of physical signs of insulin resistance (BMI, presence of acanthosis nigricans), and routine measurements are not recommended by ACOG 1.
The Clinical Problem with C-Peptide in Insulin Resistance
While C-peptide does correlate with insulin resistance in research settings 2, 3, 4, 5, this relationship is confounded by:
- Elevated C-peptide levels in insulin resistance reflect compensatory hyperinsulinemia, not the resistance itself 3, 6
- No standardized cutoffs exist for clinical decision-making in insulin resistance (unlike the well-established thresholds for hypoglycemia diagnosis) 1
- Simpler clinical assessments (BMI, waist circumference, acanthosis nigricans) provide equivalent or superior practical utility 1
What C-Peptide Actually Measures Clinically
C-peptide has three established clinical indications per current guidelines:
- Distinguishing Type 1 from Type 2 diabetes in ambiguous cases (e.g., type 2 phenotype presenting in ketoacidosis) 1, 7
- Investigating nondiabetic hypoglycemia to rule out surreptitious insulin administration 1, 8
- Insurance documentation for insulin pump therapy coverage when required by payers 1
Specific Diagnostic Thresholds (Not for Insulin Resistance)
For hypoglycemia evaluation, C-peptide ≥0.6 ng/mL (0.2 nmol/L) when plasma glucose is ≤55 mg/dL (3.0 mmol/L) indicates inappropriate insulin secretion with nearly 100% sensitivity and specificity 9, 8, 9, 8. For diabetes classification, random C-peptide >600 pmol/L (>1.8 ng/mL) within 5 hours of eating suggests preserved beta-cell function 7.
Clinical Pitfalls to Avoid
Do not order C-peptide to "assess insulin resistance" in patients with:
- Metabolic syndrome
- PCOS
- Obesity without diabetes
- Type 2 diabetes for treatment decisions
Instead, use:
- Clinical assessment: BMI, waist circumference, acanthosis nigricans
- Standard metabolic markers: Fasting glucose, HbA1c, lipid panel
- Treatment response: Therapeutic trial of metformin or lifestyle modification
The Research-Practice Gap
While recent research studies 2, 3, 4, 5 demonstrate statistical correlations between C-peptide-based indices (like 20/[Fcpep × FBG] or HOMA-IR using C-peptide) and insulin resistance, these remain investigational tools without validated clinical thresholds or demonstrated superiority over existing methods 6. The 2023 guidelines' explicit recommendation against routine use supersedes these research findings for clinical practice 1.